Specific targeting of tumour ECM using the TNFα-CSG fusion compound attracts immune cells into the tumour microenvironment which secrete a cocktail of proteases to degrade ECM, enlarge tumour vessels and increase perfusion (40). The gene discussed is TNF; the disease is neoplasm.